Cartesian Therapeutics, Inc. (RNAC) Operating margin 2016–2025
Cartesian Therapeutics, Inc. (RNAC) operating margin by fiscal year — reported operating income divided by reported revenue.
-35851.2%FY2025 · since FY2016: -428.9% → -35851.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -35851.2% | -35736.6 pp |
| FY2024 | -114.7% | +217.6 pp |
| FY2023 | -332.3% | -345.4 pp |
| FY2022 | 13.1% | +18.5 pp |
| FY2021 | -5.4% | +337.0 pp |
| FY2020 | -342.4% | +443.3 pp |
| FY2019 | -785.6% | +6415.1 pp |
| FY2018 | -7200.7% | +23612.9 pp |
| FY2017 | -30813.5% | -30384.6 pp |
| FY2016 | -428.9% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice